CD33 and acute myeloid leukemia: When tested in the first relapse setting in adults with CD33-positive de novo AML in Study MyloFrance 1, the fractionated dose-schedule of GO 3 mg/m2 days 1, 4, and 7 as monotherapy showed a 26% CR and 33% CR + CRp rate [82].